

REMARKS

Prior to entry of this amendment, claims 14, 16-27 and 30 were pending. No new claims are added and no claims are canceled. Thus, after entry of this amendment, **claims 14, 16-27 and 30 will still be pending.**

Claim 22 is amended to clarify that the immunogenic fragment is lipidated. No new matter has been introduced by this amendment.

REJECTION UNDER 35 U.S.C. §112, SECOND PARAGRAPH

Claims 22-24 are rejected under 35 U.S.C. §112, second paragraph, as allegedly being indefinite. Specifically, the Office alleges that it is unclear if the immunogenic fragment is lipidated. In response, claim 22 is amended herein to clarify that the immunogenic fragment is lipidated. Accordingly, Applicants request withdrawal of this rejection under 35 U.S.C. §112, second paragraph.

ALLOWED CLAIMS

Applicants thank the Examiner for indicating that claims 14, 16-21, 25-27 and 30 are allowed. Applicants believe claims 22-24 also are in condition for allowance.

CONCLUDING STATEMENT

It is respectfully submitted that the present claims are in a condition for allowance. Should the Examiner have further questions or comments with respect to examination of this case, it is respectfully requested that the Examiner telephone the undersigned so that further examination of this application can be expedited.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By /Jodi L. Connolly/
Jodi L. Connolly, Ph.D.
Registration No. 54,044